Acrivon Therapeutics Executives Make Significant Stock Purchases in 2026.

Acrivon Therapeutics, Inc. [ACRV] has recently announced that its Director, President and CEO, Peter Blume-Jensen, has acquired 49,000 shares at a price of $1.68 per share on January 14, 2026. Additionally, the company's Chief Financial Officer, Adam D. Levy, has purchased 8,832 shares at a price of $1.7 per share on the same date.